Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant

BACKGROUND: Antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA or adenoviral vector-based vaccines is weak in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines in KT. Here, we c...

Descripción completa

Detalles Bibliográficos
Autores principales: Seija, Mariana, Rammauro, Florencia, Santiago, José, Orihuela, Natalia, Zulberti, Catherine, Machado, Danilo, Recalde, Cecilia, Noboa, Javier, Frantchez, Victoria, Astesiano, Rossana, Yandián, Federico, Guerisoli, Ana, Morra, Álvaro, Cassinelli, Daniela, Coelho, Cecilia, de Aramburu, Belén, González-Severgnini, Paulina, Moreno, Romina, Pippolo, Aldana, López, Gabriela, Lemos, Mónica, Somariva, Lorena, López, Eliana, Fumero, Soledad, Orihuela, Carla, Rodríguez, Rosalía, Acuña, Gonzalo, Rabaza, Victoria, Perg, Nancy, Cordero, Rossana, Reisfeld, Cristina, Olivera, Paula, Montero, Paola, Nogueira, Cecilia, Nalerio, Catheryn, Orihuela, Sergio, Curi, Lilián, Burgstaller, Ema, Noboa, Oscar, Pritsch, Otto, Nin, Marcelo, Bianchi, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755301/
https://www.ncbi.nlm.nih.gov/pubmed/35198159
http://dx.doi.org/10.1093/ckj/sfab291
Descripción
Sumario:BACKGROUND: Antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after mRNA or adenoviral vector-based vaccines is weak in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines in KT. Here, we compare antibody response following vaccination with inactivated virus (CoronaVac®) and BNT162b2 mRNA. METHODS: A national multicentre cross-sectional study was conducted. The study group was composed of patients from all KT centres in Uruguay, vaccinated between 1 and 31 May 2021 (CoronaVac®, n = 245 and BNT162b2, n = 39). The control group was constituted of 82 healthy individuals. Participants had no prior confirmed coronavirus disease 2019 (COVID-19) test. Blood samples were collected between 30 and 40 days after the second dose. Serum-specific immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 Spike protein were determined using the COVID-19 IgG QUANT ELISA Kit. RESULTS: Only 29% of KT recipients showed seroconversion (36.5% BNT162b2, 27.8% inactivated virus, P = 0.248) in comparison with 100% in healthy control with either vaccine. Antibody levels against RBD were higher with BNT162b mRNA than with inactivated virus [median (interquartile range) 173 (73–554) and 29 (11–70) binding antibody units (BAU)/mL, P < 0.034] in KT and 10 times lower than healthy control [inactivated virus: 308 (209–335) and BNT162b2: 2638 (2608–3808) BAU/mL, P < 0.034]. In multivariate analysis, variables associated with negative humoral response were age, triple immunosuppression, estimated glomerular filtration rate and time post-KT. CONCLUSION: Seroconversion was low in KT patients after vaccination with both platforms. Antibody levels against SARS-CoV-2 were lower with inactivated virus than BNT162b mRNA. These findings support the need for strategies to improve immunogenicity in KT recipients after two doses of either vaccine.

Ejemplares similares